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Abstract
Background: Thrombolysis using intravenous (IV) tissue plasminogen activator (tPA) is one of few evidence-based
acute stroke treatments, yet achieving high rates of IV tPA delivery has been problematic. The 4.5-h treatment
window, the complexity of determining eligibility criteria and the availability of expertise and required resources
may impact on treatment rates, with barriers encountered at the levels of the individual clinician, the social context
and the health system itself. The review aimed to describe health system factors associated with higher rates of IV
tPA administration for ischemic stroke and to identify whether system-focussed interventions increased tPA rates for
ischemic stroke.
Methods: Published original English-language research from four electronic databases spanning 1997–2014 was
examined. Observational studies of the association between health system factors and tPA rates were described
separately from studies of system-focussed intervention strategies aiming to increase tPA rates. Where study
outcomes were sufficiently similar, a pooled meta-analysis of outcomes was conducted.
Results: Forty-one articles met the inclusion criteria: 7 were methodologically rigorous interventions that met the
Cochrane Collaboration Evidence for Practice and Organization of Care (EPOC) study design guidelines and 34
described observed associations between health system factors and rates of IV tPA. System-related factors generally
associated with higher IV tPA rates were as follows: urban location, centralised or hub and spoke models, treatment
by a neurologist/stroke nurse, in a neurology department/stroke unit or teaching hospital, being admitted by
ambulance or mobile team and stroke-specific protocols. Results of the intervention studies suggest that
telemedicine approaches did not consistently increase IV tPA rates. Quality improvement strategies appear able to
provide modest increases in stroke thrombolysis (pooled odds ratio = 2.1, p = 0.05).
Conclusions: In order to improve IV tPA rates in acute stroke care, specific health system factors need to be targeted.
Multi-component quality improvement approaches can improve IV tPA rates for stroke, although more thoughtfully
designed and well-reported trials are required to safely increase rates of IV tPA to eligible stroke patients.
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Background
Stroke causes five million deaths worldwide [1, 2] with
escalating costs to the health system [3–6]. Most stroke
cases (89 %) are admitted to hospital [7], with approxi-
mately 50 % of sufferers left deceased or dependent [8].
Thrombolysis using intravenous (IV) tissue plasminogen
activator (tPA) is one of the few evidence-based acute
stroke treatments [9, 10].
Despite the potential benefit offered by routine deliv-
ery of thrombolysis to eligible stroke patients, achieving
and sustaining high rates of IV tPA delivery has been
problematic.
While seeking treatment late is a major limiting factor
on tPA delivery [11, 12], health system factors (i.e. circum-
stances that are determined by the health organisation
or the health care provider rather than the individual)
are important in improving access to thrombolysis for
stroke patients. While there is no agreed benchmark for
rates or levels of thrombolysis in practice, substantial
change has been shown to be achievable such as an in-
crease in tPA administration rate from 4.7 to 21.4 % of
all stroke patients [13].
The narrow treatment window of 4.5 h from stroke
onset, negative impacts of inappropriate treatment,
along with the multi-step, multi-disciplinary testing, and
decision-making process needed to determine thromboly-
sis eligibility would indicate that complex interventions
are required to change thrombolysis rates [14]. Complex
interventions are generally defined as those which involve
a number of interacting components, require a number of
behaviours or difficult behaviours, involve a number of
groups or organisational levels and have a number of out-
comes [14], each of which is directly relevant to thromb-
olysis for acute stroke. Barriers to treatment include
delays in stroke recognition by staff [15], delays in obtain-
ing and interpreting radiology imaging [16], inefficiencies
in emergency stroke care and delays in obtaining treat-
ment consent [17].
Study of the diffusion of new technologies indicates
that while some innovations are largely adopted in less
than 5 years [18], others may fail to become common-
place due to barriers or failures at a higher level [19]. In
these contexts, the use of theoretical frameworks such
as the Behaviour Change Wheel (BCW) [20] can be
helpful to clarify the range of factors which may need to
be addressed in order to effect change. The BCW de-
scribes the three essential conditions for behaviour
change to occur: capability, opportunity and motivation;
nine intervention functions and seven policy categories
are required for whole system change [20]. Models and
frameworks such as the BCW emphasise the importance
of intervening not only at the level of the individual but
also at an organisational or system level and at the
broader policy level. While policy-level factors such as
financial incentives may impact on thrombolysis over
the long term [21], in the short to medium term, health
service providers may have the greatest potential impact
by acting at a health system or organisational level.
A number of cross-sectional studies have described
associations between higher stroke tPA rates and system-
level factors such as hospital size and hospital type
[22, 23] or characteristics such as staffing [24] or
stroke certification [25–28]. System-level approaches
have been recommended to improve access to IV tPA
and increase the proportion of patients receiving the
treatment, including telemedicine and centralised hub
and spoke models [29–31]. Some studies have described
successful attempts to apply hospital pre-notification sys-
tems [13] or quality-improvement approaches (e.g. analys-
ing performance, with systematic efforts to improve it,
ultimately resulting in better health outcomes) [32, 33], to
increase tPA implementation for stroke.
However, system changes require substantial resources
and engagement with quality improvement programmes.
To our knowledge, there are no published reviews of a
broad range of evidence-based health system factors as-
sociated with increased IV tPA administration rates for
stroke.
Aims
The aim of this study is to identify the following:
 Health system factors associated with higher rates of
IV tPA administration for ischemic stroke
 The effectiveness of system-focussed intervention
strategies, which meet Cochrane Collaboration
Evidence for Practice and Organization of Care
(EPOC) study design guidelines, in improving IV
tPA rates for treatment of ischemic stroke
Methods
Search strategy
The literature review in MEDLINE, CINAHL, EMBASE
and PsycINFO spanned from January 1997 to May 2014
and was performed as title, abstract and full-text review
by three independent reviewers, with ambiguous articles
discussed as a group to reach agreement. The search
period was selected to align with the 1996 approval of
the “clot-buster” drug [34] and the release of the first
tPA stroke guidelines [35]. Search terms were confirmed
in consultation with clinical stakeholders and a medical
librarian. Available MeSH headings were used; other-
wise, a “title” field search was conducted.
Limitations included published original research,
English language, humans, adults, and used a combination
of keyword searches of “tpa.m_titl” OR “rtpa.m_titl” OR
“Tissue Plasminogen Activator OR Tissue Plasminogen
Activator.m_titl” OR “Fibrinolytic Agents OR Fibrinolytic
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Agents.m_titl” OR “Recombinant Proteins OR Recombin-
ant Proteins.m_titl” OR “Thrombolytic Therapy OR
Thrombolytic Therapy.m_titl” AND “Stroke OR Stroke.m_
title” OR “Brain Ischemia OR Brain Ischemia.m_titl” OR
“Cerebral Hemorrhage or Cerebral Hemorrhage.m_titl”.
Inclusion criteria
The inclusion criteria are as follows:
 Studies that quantitatively assessed modifiable health
system factors influencing rates of IV tPA for stroke;
or
 Intervention studies aiming to improve rates of IV
tPA administration for stroke
Exclusion criteria
The exclusion criteria are as follows:
 Solely addressing patient characteristics such as age,
race, education, income or clinical eligibility for
thrombolysis
 No denominator for calculating tPA rates or not
reporting a tPA rate
 Solely assessing intra-arterial tPA
 Addressing only community-directed or patient-




Using an extraction template, the following health sys-
tem factors were extracted: sample characteristics, sam-
ple size, response rate, descriptors of setting, data
collection method, rate and proportion of IV tPA admin-
istration, system factors addressed in relation to tPA
delivery, factors affecting IV tPA rates, tPA criteria/
guidelines and tPA time window. Using existing frame-
works such as the BCW to categorise the identified
health system factors was not successful as a number of
the strategies could be categorised as having multiple
intervention functions. Only three of the nine interven-
tion functions and two of the seven policy functions de-
scribed in the BCW were identified in the review.
Therefore, a consensus process was used among the au-
thors to identify practice-relevant categories under
which to present the observational studies.
Interventions
Intervention studies were reviewed and categorised ac-
cording to whether or not they met criteria for any of
the four experimental designs defined and recom-
mended by the EPOC design criteria. Data extracted
were as follows: study design; setting; target group;
study duration; intervention allocation; unit of analysis;
allocation concealment; blinding; eligibility criteria;
sample size; representativeness of sample; intervention
conditions; outcome measures; statistical analysis; and
findings.
Quality control
Quality control involved second coding of a random
sample of articles (10 %) at each review stage, i.e. initial
extraction of studies and exclusion of ineligible studies
(AR, SR, CP). Extracted data from all included studies
were double-coded in full (AR, SR, CP, CK, JA, EK) and
checked for agreement (AR). Agreement rates exceeded
90 % at all stages. All remaining differences in inclu-
sions, exclusions and extracted data were discussed ac-
cording to documented principles until consensus was
reached, with subsequent re-coding completed wherever
necessary.
Analysis
For the experimental studies, synthesis of the data in-
volved meta-analysis where possible. Only studies which
had pre- and post-test data specifying the rate of thromb-
olysis for intervention versus control groups were in-
cluded in the meta-analysis. For the four study outcomes
that were sufficiently similar, a pooled meta-analysis of
outcomes was conducted using StatsDirect (version 2.7.9.,
Cheshire, UK). Heterogeneity was checked using I2 and if
high, random effects (DerSimonian-Laird method) pooling
was used. Narrative synthesis was used to describe out-
comes for the remainder of the experimental studies
which could not be included in the meta-analysis due to
heterogeneity of outcomes. Narrative synthesis [36] in-
volved verbal descriptions of the extracted data. For the
observational studies, data synthesis involved tabulation of
whether the study found a significant association with
thrombolysis rate for any review-relevant factor followed
by comparative narrative synthesis.
Results
The search resulted in 4323 citations (MEDLINE n = 1947,
EMBASE n = 1760, PsycINFO n = 46, CINAHL n = 570).
As indicated in Fig. 1, 34 studies reported associations be-
tween health system factors and IV tPA rates for ischemic
stroke. Seven intervention studies that reported an im-
provement in IV tPA rates met the EPOC design criteria.
Forty-seven intervention studies were excluded as being
either pre-test-post-test designs with no control group or
pilot tests with post-test only data. The types of interven-
tion strategies studied in the 47 excluded publications in-
cluded the following: the introduction of stroke units or
“code-stroke” protocols; support for regional sites (e.g.
hub and spoke models, telemedicine); changes in hospital
protocols, staffing or rostering; and the “Get With The
Guidelines” programme [37].
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Health system factors
Table 1 summarises the 34 studies exploring associations
between thrombolysis rates and health system factors.
The majority (n = 19) of studies conducted multivariable
analyses including both health system and patient fac-
tors. Health system factors were categorised post hoc
and those with predominantly positive associations with
tPA rates were as follows:
 Travel time and location: e.g. urban rather than
rural location, or a centralised/“hub” model linking
outlying centres with other, generally larger, centres
(environmental restructuring)
 Training, skills and expertise: treatment by
neurologist or in a neurology department; admission
to a stroke unit; treatment at academic/teaching
hospital; treatment at a hospital with higher volume
of stroke admissions or neurology beds; or
accreditation as a “medical centre” (training and
education)
 Facilities and staffing: having a neurologist, stroke
nurse or stroke team; neurological or neuroimaging
services; and weekend arrival (service provision)
 Organisational elements: use of stroke-specific
protocols or transfer by ambulance/mobile
emergency team rather than other means (guidelines
and regulation)
The terms in parentheses refer to BCW intervention
functions and policy categories.
Effectiveness of system-focussed interventions
Two intervention studies [38, 39] compared telemedi-
cine with a telephone-only approach under the “hub and
spoke” model. This group were too diverse in method-
ology and measurement to be included in a pooled
analysis. Therefore, a narrative outcome description is
provided. Neither of the telemedicine studies found a
significant difference in IV tPA rates or patient out-
comes, with one [38] aiming to assess feasibility rather
than effectiveness resulting in limited power to find any
effect. Meyer et al. [39] identified significantly higher
rates of correct treatment decisions in telemedicine-
treated patients compared to the telephone-only group.
A third study [40] explored a hub and spoke tele-
consultation approach for one group of sites while a
control group of sites proceeded with usual care. All
sites found significant increases in IV tPA, while only
tele-consultation sites significantly reduced mortality.
Four studies [32, 41–43] explored approaches using
quality improvement methods. Of these, two [41, 42]
found a significant effect on IV tPA rates and patient
outcomes based on modified Rankin scores. Scott et al.
[43] found a significant effect on IV tPA rates for some
analyses, with no significant effect on service delivery
Fig. 1 Inclusion and exclusion of citations
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measures or patient outcome. Schwamm et al. [32] re-
ported that involvement in the Get With The Guidelines
Stroke programme was associated with an improvement
over time in thrombolysis rates for patients arriving
within 2 h of symptom onset.
The four quality improvement studies were included
in pooled analysis of tPA rates. As the heterogeneity of
the studies was high (I2 = 98 % [95 % CI = 97.1 to
98.5 %]), a random-effects model was used, and the
pooled estimate should be treated with caution. A bor-
derline significant effect was found, with a pooled odds
ratio of 2.1 (95 % CI = 1.0 to 4.5) and; X2 = 3.783689, df = 1,
p = 0.05. The seven intervention studies are described in
Table 2.
Discussion
This systematic review brings together the empirical evi-
dence regarding potential strategies for improving
thrombolysis rates for acute stroke. The review data
provide a basis on which stroke service providers can
identify which strategies are more likely to be good in-
vestments for increasing rates of thrombolysis. As per
the literature regarding complex interventions [14] and
frameworks such as the BCW [20], a range of strategies
Table 1 Health system factors associated and not associated with higher thrombolysis rates
Health system factors Studies finding no association
with higher thrombolysis rate
Studies finding a significant association
with higher thrombolysis rate
Travel time and location (environmental restructuring)a
Shorter transport time or distance to hospital [48–51] [52, 53]
Urban (vs rural) – [54–56]
Centralised (hub model) – [57]
Training, skills and expertise (training and education)a
Treated by a neurologist – [49, 56], [58] (no statistical test)
Admitted to or treated in a neurology department or stroke unit [59] [60, 61]
Academic/teaching hospital [56] [55, 60, 62–64], [65]b
Continuing medical education/formal stroke training [33, 62] [25]
Higher volume of stroke admissions/number of neuro beds [56, 59] [49, 61, 66]
Accreditation as medical centre – [49]
Facilities and staffing (service provision)a
Emergency medical service or emergency department [33] [25]
Neurologists, stroke nurse, stroke unit or team [33] [25, 61, 62, 67]
Neurological/neuroimaging services [62] [25, 68]
Laboratory services [25, 62] –
Larger/higher volume hospital [56, 61] [69]
Arrival during “on” hours [57, 70] –
Arrival on weekend [70] [49, 71]
24 h or rapid CT/MRI [62] –
Intensive care unit (cat 1) [72] –
Stroke allocated beds [33] –
Organisational elements (guidelines and regulations)a
Commitment of medical organisation or stroke centre director [25] [62]
Quality improvement outcomes or activities [25, 62] –
Pre-hospital notifications or triage tool [73, 74] [75]
Stroke-related certification [76] [77]
Ambulance agreements/protocols or training [33] [33] (borderline positive association)
Who interprets CT [33] –
Stroke-specific protocols [62] (acute stroke protocol) [25, 33, 62]
Transfer by a mobile emergency team or ambulance – [48, 50, 78, 79]
aTerms in parentheses refer to BCW intervention functions and policy categories
bSignificant in univariate analysis only
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Patient: n = 222
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2. mRS (score ≤2).
Fisher’s exact test:
difference in tPA rate,
functional outcomes
tPA rate: Int-1,
28 %; Int-2, 23 %
(OR = 1.3 [0.7–2.5],
p = NS).
Service delivery:
1. Greater in Int-1
compared to
Int-2 (98 vs 82 %,
OR = 10.9 [2.7–44.6],
p < 0.001).



















































Phase 1: n = 277
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Phase 2: n = 499
(266 vs 233)
Phase 3: n = 150
(80 vs 70)




































8.6, 11.2 % (p < 0.007);
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Service delivery:
1. No difference in
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year 5 (72.8 %;
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Patient outcome:
1. NS over time
Greatest improvement
(composite performance/
program year in GWTG)
in hospitals with more
beds (p< 0.0001), larger
annual stroke volume
(p< 0.0001) and teaching
status (p< 0.0001)








































































between tPA rates at
pre- and post-
intervention periods
tPA rate: ITT: Int
(pre and post), 1.25
and 2.79 %; C (n = 1;
pre and post), 1.25
and 2.10 %. Int vs C,
p = NS.
Target analysis:
Int (pre and post), 1.0
and 2.62 %; C (pre and
post),1.09 and 1.72 %.
Int vs C, RR = 1.68
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tPA rate: Hub sites:
(pooled) increased 4.2
to 7.7 % (p < 0.0001);
Spoke sites: (pooled)
increased 1.1 to 5.9 %
(p < 0.0001); C:
(one hospital only)
increased 0.8 to 5.7 %





site only (10.3 to
7.3 %, p = 0.03)
Abbreviations: C control group, CBA controlled before and after trial, CT computer tomography, ED emergency department, EMS emergency medical service, RCT randomised controlled trial, Int intervention group, ITS











or factors are related to achieving change in thromboly-
sis rates. Of note is that the literature only addresses
three of the nine intervention functions and two of the
seven policy categories raised in the BCW framework,
suggesting a much wider range of strategies could be
tested in the future.
A small number of system-related factors are associ-
ated with higher rates of IV tPA administration for is-
chemic stroke. Systems-change interventions, based on
multi-component quality improvement approaches, can
increase the proportion of eligible stroke patients receiv-
ing IV tPA.
The observational literature regarding factors associ-
ated with higher stroke tPA rates was heterogeneous in
methodology and types of factors assessed, but it is un-
clear whether each study had sufficient power to detect
an association for each factor. The literature indicates
that health systems should aim to ensure that most
stroke patients are treated in a way that minimises ac-
cess disadvantages for rural populations; maximises ac-
cess to neurological and stroke-specific expertise and
experience; ensures stroke units are widely available; and
implements stroke-specific protocols. The association of
higher IV tPA rates with treatment at a teaching hospital
or a hospital with larger stroke or IV tPA treatment vol-
ume suggests that expertise and experience within such
settings is key to increased IV tPA rates. The mixed find-
ings regarding the importance of treatment at a larger
hospital and arrival during “on” hours or weekends indi-
cate that greater size and availability of staff alone do
not produce higher IV tPA rates. However, it must be
noted that observational studies cannot be used to draw
definitive conclusions regarding causation. The observa-
tional studies were also largely retrospective in design
and had limited capacity to identify and assess con-
founding factors. Therefore, a greater focus must be
directed towards the data from the experimental or
intervention studies.
Organisational elements such as stroke certification
and quality improvement activities were not associated
with higher IV tPA rates. One study [25] failed to find
an association between facilities, staffing and organisa-
tional elements and quality improvement outcomes or
activities. These elements are often the focus of system-
change interventions and can be resource intensive to
implement. Therefore, robust experimental studies are
essential to providing clarity about cost-effective ap-
proaches to improved IV tPA rates. Organisational ele-
ments such as stroke-related certification or time on the
Get With The Guidelines programme did not increase
IV tPA rates.
The intervention studies suggest that while quality-im-
provement or system-change interventions can be ef-
fective in increasing IV tPA rates, studies are
heterogeneous and effects may be small or inconsist-
ent. The PRACTISE trial [41] found a positive effect
on IV tPA rates and patient functioning following a
Breakthrough Series intervention. The INSTINCT trial
[43] reported a positive effect only when the analysis
focussed on a subset of study sites. The INSTINCT
intervention placed less emphasis on collaborative
meetings compared to the PRACTISE trial but in-
cluded stroke champions, education/support for treat-
ment decision making and performance feedback [43].
The Morgenstern et al. study [42] identified a greater
increase in IV tPA rates in intervention sites, com-
pared to control sites.
This study [42] differed from the two other studies by
including community-focussed mass media. It also in-
cluded hospital-based change via multi-disciplinary
teams, development of emergency department protocols,
problem solving, medical education and performance
feedback. Given the small number of hospitals involved,
the choice of patient rather than hospital as the unit of
analysis, and the lack of any head-to-head analysis across
groups, some caution should be applied to interpreting
the results of the Morgenstern et al. study [42].
Other studies support the finding that quality im-
provement strategies can provide modest positive effects
on other aspects of stroke care [32, 44, 45]. The “Stroke
90:10” trial found an 11 % relative improvement in some
aspects of initial assessment and care for stroke patients
following collaborative quality improvement [45]. An-
other study involving workshops, education, site-based
teams, performance feedback and decisional support
suggests that improvements in thrombolysis occurred
over time [32]. While the study could be classified as an
interrupted time series based on quarterly measurements
over 4 years, the analysis did not follow usual ap-
proaches to analysing time-series data. Although the cost
of IV tPA administration was not addressed in the
reviewed studies, the scope of multi-component, multi-
site interventions suggests the resources required are
substantial.
Two studies [38, 39] compared telemedicine with a
telephone-only approach, focusing on environmental re-
structuring rather than quality improvement to increase
IV tPA delivery. Conclusions are difficult to make, as
neither study indicated sufficient power to detect a dif-
ference in IV tPA rates. The study of tele-consultation
compared to usual care [40] suggested, but did not
conclusively demonstrate, patient outcome benefits,
given a failure to statistically examine experimental
versus control site outcomes. A later pooled analysis
confirmed telemedicine consultations were not associ-
ated with increased thrombolysis rates [46]. While
these changes may increase access to expert care, they
lack robust evidence.
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Observational and intervention data suggest that opti-
mising IV tPA administration requires availability of ex-
pertise and protocols. Intervention studies suggest more
in-depth reporting of the degree to which various inter-
vention strategies may assist in understanding the best
way forward. While multi-component approaches appear
promising, two important questions emerge:
 Could a comprehensive intervention approach,
encompassing the range of strategies represented in
the reviewed studies, achieve a more substantial
increase in IV tPA rates than that found to date? If
so, what is the cost-benefit?
 Could a more streamlined quality improvement
approach be identified, using a subset of elements?
This may require comprehensive and systematic
approaches to study the implementation of prior
and future multi-component interventions, followed
by trials using a subset of “best-bet” strategies.
The broader context is also important to consider,
such as the financial incentives to hospitals for or against
thrombolysis delivery in certain settings [21]. Adapting
system thinking where components of the health system
are dynamic and interlinked may assist in further under-
standing the network of relations and feedback loops
impacting on the uptake of new innovations [47]. It may
also be useful to develop a broader theoretical frame-
work that could be applied to future studies in this area.
Limitations should be considered when interpreting
the study tables: firstly, the reported rates of IV tPA (see
Table 2) are dependent on denominator and eligibility
criteria, which can affect the power of the study to de-
tect a difference in the outcome; secondly, the variability
in factors explored across studies of descriptive health
system factors limits the ability to make comparisons
among studies; and finally, the nature of changing care
at a system level limits design rigour such as the ability
to blind sites to group allocation. As a “Google” search
was not used, a small number of unpublished studies
may not have been identified.
Conclusion
Access to teaching hospitals and hospitals with larger
stroke and IV tPA treatment volumes is associated with
increased IV tPA administration rates for stroke, al-
though results should be viewed against variability in
eligibility criteria and type of denominator used. Inter-
ventions aiming to increase rates of IV tPA are resource
intensive and comparisons between studies are difficult
due to insufficient power and limitations in study ana-
lysis. More empirical data regarding the effects of efforts
to improve access to thrombolysis for those living long
distances (e.g. mobile thrombolysis) from a tPA-capable
hospital and 24-h availability of expertise in acute
stroke care are required, as is more thoughtfully de-
signed and well-reported trials of quality improvement
interventions.
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